Peter Fasching is tweeting
Joined December 2020
- Tweets104
- Following92
- Followers159
- Likes131
AGO-B Study ESRA starting. ESR1 mutation prevalence in first line aBC (clinicaltrials.gov/study/NCT…). Today the new QIAcuityDx System arrived. Ready for ESR1 testing. Implementation of Serena-6 testing will help postponing progression. Good for patients.
#breastcancer #esr1 #serena
Serena-4 press releaase: astrazeneca.com/media-centre…
Now the last major piece of information missing is the pionERA study (clinicaltrials.gov/study/NCT…)
One thing is clear: the path for camizestrant according to Serena-6 seems pretty much cleared. Identify ESR1 before SERD in aBC.
MonarchE reported an overall survival benefit of abemaciclib in high risk early breast cancer. investor.lilly.com/news-rele…
Likely we see that data at this years ESMO in Berlin esmo.org/meeting-calendar/es… Good chance we also see an update of NATALEE. Great that these studies mature.
Mal eine andere Art der Publikation: Mammografie-Screening senkt Mortalität wahrscheinlich um 20 bis 30% (bei allen Schwierigkeiten solcher Auswertungen). Toller Erfolg für die Prävention. Prävention muss weiter besser werden!!!
nbn-resolving.de/urn:nbn:de:…
doris.bfs.de/jspui/bitstream…
Now Destiny-B06 Study with a positive CHMP opinion
ema.europa.eu/en/medicines/h…
Then T-Dxd will possible in ultralow HER2 expressing tumors and without previous chemotherapy. Good to have more therapeutic options for new therapy sequences.
#breastcancer #tdxd #ultralow
Serena-6 study seems to be positive - another milestone in individualized healthcare for patients with advanced breast cancer
astrazeneca.com/media-centre…
Hopefully we see this data at ASCO2025
#breastcancer #serd #asco2025
Neoadjvuant Radiotherapy: new insights with important information that might be useful current clinical trial design
sciencedirect.com/science/ar…
#breastcancer #radiotherapy
Great month for Datopotamab-deruxtecan for HRpos/HER2neg aBC patients: After Approval in the US two weeks ago:
fda.gov/drugs/resources-info…
Also Approval recommendation by the EMA yesterday
ema.europa.eu/en/medicines/h…
INAVO120 Study seems to be positive for overall survival. Excellent news for patients !!!
roche.com/media/releases/med…
Assuming data will be presented at ASCO in 4 months we have to wait for this data quite some time. Maybe find a way to immendiately share the data, when anndouncing?
Good for the therapy landscape: T-Dxd approved in the U.S. in the DB-06 Population (Patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies).
astrazeneca.com/media-centre…
nejm.org/doi/full/10.1056/NE…
Gipfelstürmer Neuauflage 2025 in der "wahren Hauptstadt Deutschlands" (Zitat eines berühmten Gynäkologen): aurikamed.de/gs2025
AGO Breast Study Group retweeted
Nächste Woche geht es wieder los! Der #SABCS24 öffnet seine Türen! #onkowissenTV ist natürlich wieder live vor Ort und berichtet von den neuesten Daten! Ganz neu dieses Jahr: der onkowissenTV Livestream mit allen wichtigen Updates des Jahres 2024 im Bereich #Mammakarzinom. Jetzt Platz sichern und nicht verpassen, am 14.12. um 14:30 MEZ: onkowissen.tv/livestream
@DLueftner @Mbpzp2 @HartkopfAndreas @hckol @volkmar_mueller @juliaradosa @SABCSSanAntonio
Kisqali - opinion on variation to marketing authorisation | EMA ema.europa.eu/en/medicines/h…
After the U.S., now positive opinion on early breast cancer ribociclib use a consequence of positive outcome data of NATALEE oncologypro.esmo.org/meeting…
#breastcancer #ribociclib #natalee
Keynote-522 every third breast cancer death prevented.
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer | New England Journal of Medicine nejm.org/doi/10.1056/NEJMoa2…
Yesterday 4yr survival update of NATALEE: tinyurl.com/2zv8kcv6
Today FDA Approval for Ribociclib in the adjuvant setting: tinyurl.com/mum2m68h
#breastcancer
Gestern 4yr survival update von NATALEE: tinyurl.com/2zv8kcv6
Heute in den USA die Zulassung für high risk HRpos/HER2neg eBC: tinyurl.com/mum2m68h
#brustkrebs #breastcancer
Breast Cancer Screening Interval: Screening Ergebnisse anders herum. Screening scheint auch bei jungen Frauen das Stadium günstig zu beeinflussen. Zeit, auch das Vorgehen in Deutschland neu zu disktuieren? ascopubs.org/doi/10.1200/JCO…
Die finalen Mammografie-Screening-Empfehlungen, die das Eintritts-Alter in den USA auf 40 senken, sind verabschiedet
uspreventiveservicestaskforc…
Zeit, sich auch in Deutschland die Epidemiologie und das Erkrankungsalter noch einmal anzuschauen?
#mammakarzinom #screening #mammografie
Jetzt anmelden: AGO Mammakarzinom State of the Art 2024 – alle neuen Therapie-Empfehlungen der Kommission Mamma live in Frankfurt am 02.03.2024. Auch virtuelle Teilnahme möglich.
ago2024.de
New analysis in HRPos/HER2neg BC patients shows the prognosis of the groups according to inclusion/exclusion criteria of MonarchE and NATALEE in a German Cohort study of letrozole treated HRpos/HER2neg patients. dx.doi.org/10.2139/ssrn.4676…